Beta bloccanti

<p>Applications A metabolite of Atorvastatin, a selective, competitive HMG-CoA reductase inhibitor. Atorvastatin is the only drug in its class specfically indicated for lowering both elevated LDL-cholesterol and triglycerides in patients with hypercholesterolemia.<br>References Smith, S., et al.: Am. J. Cardiol., 80, 10H (1997), Jacobsen, W., et al.: Drug Metab. Dispos., 28, 1369 (2000), Istvan, E., et al.: Science, 292, 1160 (2001), Tabernero, L., et al.: J. Biol. Chem., 278, 19933 (2003), Bratton, L., et al.: Bioorg. Med. Chem., 15, 5576 (2007),<br></p>

<p>Stability Hygroscopic<br>Applications A metabolite of Nebivolol.<br>References Stoleru, L., et al.: J. Cardiovasc. Pharmacol., 22, 183 (1993), Cockcroft, J., et al.: J. Pharmacol. Exp. Ther., 274, 1067 (1995), Stoschitzky, K., et al.: Cardiovasc. Drugs Ther., 16, 133 (2002), Poole-Wilson, P., et al.: Lancet, 362, 7 (2003),<br></p>

<p>Applications Mixed β-adrenergic blocker and serotonin 5HT1A-receptor antagonist. Antihypertensive; antianginal; antiarrhythmic; antiglaucoma.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Dreshfield, L. J., et al.: Neurochem. Res., 21, 557 (1996); Perez, V., et al.: Lancet, 349, 1594 (1997)<br></p>

<p>Stability Hygroscopic, Light Sensitive, Temperature Sensitive<br>Applications Fluvastatin 3-Hydroxy-4,6-diene Sodium Salt is a metabolite of Fluvastatin (F601250), a synthetic HMG-CoA reductase inhibitor. Antilipemic.<br>References Yuan, J., et al.: Atherosclerosis, 87, 147 (1991), Tse, F.L.S., et al.: J. Clin. Pharmacol., 32, 630 (1992), Dain, J.G., et al.: Drug Metab. Disposit., 21, 567 (1993),<br></p>

<p>Applications A metabolite of Carvedilol (C184625), a nonselective β-adrenergic blocker with α1-blocking activity.<br>References Sponer, G., et al.: J. Cardiovasc. Pharmacol., 9, 317 (1987), Fujimaki, M., et al.: Xenobiotica, 20, 1025 (1990), Ruffolo, R., et al.: Eur. J. Clin. Pharmacol., 38, S82 (1990), Clohs, L., et al.: J. Pharm. Biomed. Anal., 31, 407 (2003),<br></p>

<p>Applications Carvedilol-d5 is the labelled analog of Carvedilol, a nonselective β-adrenergic blocker with α1-blocking activity. Carvedilol is an antihypertensive used in the treatment of congestive heart failure.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Hirohashi, M., et al.: Arzneim.-Forsch., 40, 735 (1990), Packer, M., et al.: N. Engl. J. Med., 334, 1349 (1996),<br></p>

<p>Stability Hygroscopic<br>Applications rac-4-Hydroxy Propranolol Hydrochloride is a metabolite of Propranolol.<br>References Walle, T., et al.: Drug Metab. Dispos., 13, 204 (1985), Mason, R., et al.: J. Med. Chem., 34, 869 (1991), Anderson, R., et al.: Biochem. Pharmacol., 52, 341 (1996), Hung, D., et al.: J. Pharmacol. Exp. Ther., 297, 780 (2001),<br></p>

<p>Impurity Diltiazem EP Impurity F<br>Applications Desacetyl Diltiazem (Diltiazem EP Impurity F) is a metabolite of Diltiazem (D460620).<br>References Shallcross, H., et al.: Br. Med. J., 295, 1236 (1987), Yeung, P.K.F., et al.: Drug Metab. Dispos., 18, 1055 (1990), Cashman, J.R., et al.: J. Med. Chem., 34,2049 (1991),<br></p>

<p>Applications Dabigatran Carboxamide Ethyl Ester is an impurity of Dabigatran Etexilate Mesylate (D100150) which is a nonpeptide, direct thrombin inhibitor.<br>References Hauel, N., et al.: J. Med. Chem., 45, 1757 (2002); Mungall, D., et al.: Curr. Opin. Invest. Drugs, 3, 095 (2002); Stangier, J., et al.: J. Clin. Pharmacol., 45, 555 (2005)<br></p>

<p>Applications A vascularly inactive metabolite of Carvedilol (C184625). A novel antihypertensive agent, is a potent antioxidant.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Sponer, G., et al.: J. Cardiovasc. Pharmacol., 9, 317 (1987), Rapola, J., et al.: Lancet, 349, 1715 (1997), Gao, F., et al.: Eur. J. Pharmacol., 406, 109 (2000),<br></p>

<p>Applications Atorvastatin impurity. Atorvastatin Methyl Ester<br>References Graul, A., et al.: Drugs Future, 22, 956 (1997),<br></p>

<p>Applications A metabolite of Eplerenone. Used in combination therapy for treatment of cardiovascular disorders.<br>References Staessen, J., et al.: J. Endocrinol., 91, 457 (1981), de Gasparo, M., et al.: J. Pharmacol. Exp. Ther., 240, 650 (1987), MacFadyen, R., et al.: Cardiovasc. Res., 35, 30 (1997),<br></p>

<p>Applications Cardioselective β-adrenergic blocker. Antihypertensive, antianginal, antiarrhythmic (class II).<br>References Caplar, V., et al.: Anal. Profiles Drug Subs., 13, 1 (1984),<br></p>

<p>Impurity Metoprolol EP Impurity D<br>Applications 3-[4-(2-Methoxyethyl)phenoxy]-1,2-propanediol (Metoprolol EP Impurity D) is a new byproduct detected in Metoprolol tartrate. Metoprolol (M338790) impurity.<br>References Erickson, M., et al.: J. Pharmac. Biomed. Anal., 13, 567 (1995),<br></p>

<p>Impurity Atorvastatin EP Impurity G<br>Applications Atorvastatin derivative.<br></p>